CHS genotyped 3,980 participants free of cardiovascular disease at baseline with available DNA and consent to genetic testing. After exclusions for call rate <95%, sex mismatch, or discordance with prior genotyping, 3,291 white participants remained. Of these, 3,140 had pulmonary function measures and complete covariate information.
